Heartflow

HTFL on Nasdaq. Heartflow sells software that helps doctors diagnose heart artery disease. Market value $4.2bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to September 2026. Quality checks use five annual reports, the latest for the year to December 2025.

We can't read total debt from the filing, so debt is left out.

Should I look at this?

Not a fit for our list right now

Why it could be worth it

Nothing stands out yet.

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to September 2026
-1.4%low

For every $100 of what the whole company costs, it produced $-1.37 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to September 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: not known. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

$46.69 a share, 132% above its 1-year low

Over the past year the price has ranged from $20.13 to $60.65.

Pays no dividend

Prices from Friday’s close (20 November).

Five years of cash, in billions

-0.1
-0.1
202512 monthsto Sep '26
Revenue
$176m
Operating margin
-36.4%
Debt to equity
n/a
Shares outstanding
0.09bn

Health checks

  • Free cash flow positive0 of 1 years
  • Accounting checksSkipped: company is not yet profitable
  • DebtUnknown
  • Revenue growth, five yearsUnknown
  • Buying back its own sharesRoughly flat

The quarter to September 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $73 million last quarter, up 57% on a year ago.
  • A loss of $12 million, compared with a loss of $51 million a year ago.
  • 78% more shares than a year ago. Each share owns a bit less of the company.
Sales by quarter
Sales by quarter
Quarter toAmount
June 2025$43m
September 2025$46m
December 2025$49m
March 2026$53m
June 2026$64m
September 2026$73m
Profit by quarter
Profit by quarter
Quarter toAmount
June 2025-$9m
September 2025-$51m
December 2025-$24m
March 2026-$27m
June 2026-$16m
September 2026-$12m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
18 March 2026
Next quarterly (estimated, 10-Q)
11 February 2027

Who owns it

None of the long-term investors we follow own it. 193 funds in all.

Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

5 investors own more than 5%.

  • HCPCIV 1, LLC
    Passive investor
    7.9%
    Since 11 August 2025
  • at least 6.4%−2.7 pts
    (filed with 3 related holders)
    Since 30 September 2026
  • BlackRock, Inc.
    Passive investor
    5.7%
    Since 30 June 2026
  • FMR LLC
    Passive investor
    at least 5.7%
    (filed with 1 related holder)
    Since 30 September 2025
  • BCLS Fund III Investments, LP
    Passive investor
    5.1%−4.7 pts
    Since 30 September 2026
  • Sold down below 5%
    Since 24 March 2026
  • Hayfin Management Holdings Limited
    Passive investor
    Sold down below 5%
    Since 6 February 2026

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 1 insider bought $1m of shares on the open market. 4 sold $33m, $33m of it under preset trading plans.

  • Rogers Campbell
    Chief Medical Officer
    Sold
    under a preset trading plan
    Date
    17 November 2026
    Shares
    36,345
    Price
    $46.39
    Value
    $2m
  • Farquhar John C.M.
    Chief Executive Officer, Director
    Sold
    under a preset trading plan
    Date
    10 November 2026
    Shares
    38,900
    Price
    $55.74
    Value
    $2m
  • Verghese Vikram
    Chief Financial Officer
    Sold
    under a preset trading plan
    Date
    9 November 2026
    Shares
    3,587
    Price
    $53.15
    Value
    $190,649
  • Rogers Campbell
    Chief Medical Officer
    Sold
    under a preset trading plan
    Date
    22 October 2026
    Shares
    12,157
    Price
    $55.01
    Value
    $668,757
  • Rogers Campbell
    Chief Medical Officer
    Sold
    under a preset trading plan
    Date
    22 October 2026
    Shares
    23,933
    Price
    $55.01
    Value
    $1m
  • Farquhar John C.M.
    Chief Executive Officer, Director
    Sold
    under a preset trading plan
    Date
    12 October 2026
    Shares
    38,900
    Price
    $49.57
    Value
    $2m
  • Rogers Campbell
    Chief Medical Officer
    Sold
    under a preset trading plan
    Date
    18 September 2026
    Shares
    12,156
    Price
    $50.15
    Value
    $609,623
  • Rogers Campbell
    Chief Medical Officer
    Sold
    under a preset trading plan
    Date
    18 September 2026
    Shares
    19,682
    Price
    $50.15
    Value
    $987,052
  • Verghese Vikram
    Chief Financial Officer
    Sold
    under a preset trading plan
    Date
    18 September 2026
    Shares
    16,766
    Price
    $50.75
    Value
    $850,926
  • Verghese Vikram
    Chief Financial Officer
    Sold
    under a preset trading plan
    Date
    17 September 2026
    Shares
    7,579
    Price
    $50.11
    Value
    $379,816

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 18 Mar 2026, plus the 10-Q filed 12 Nov 2026 and 4 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.